CAR-T Therapy, CARTITUDE-1 Ciltacabtagene Autoleucel in RRMM Patients | Yi Lin, MD, PhD | ASCO 2023

Worldwide Drug Toxicity Trends for MM | Shahzad Raza, MD & Majid Jaberi-Douraki, PhD | ASCO 2023

Phase 1 Therapy PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023

DREAMM-3 - Blenrep (Belmaf) vs. PomDex for Relapsed/Refratory Myeloma | Katja Weisel, MD | ASCO 2023

Barriers in Accessing Myeloma Care in Special Populations | Shakira Grant, MBBS | ASCO 2023

Results of Bispecific Antibody Combination in Advanced Myeloma | Yael Cohen, MD | ASCO 2023

Exciting Advances in Myeloma Treatment | Timothy Schmidt, MD | ASCO 2023

Bispecific Antibody Therapy in Relapsed/Refractory Myeloma | Meera Mohan, MD, MS, FACP | ASCO 2023

The Role of Lifestyle on MGUS Progression | Betsy O’Donnell, MD | ASCO 2023

(Guest Lecture): June 2023 - The Role of Lifestyle on MGUS Progression with Betsy O’Donnell, MD | ASCO 2023

LINKER-MM1 Study: Linvoseltamab (REGN5458) in Relapsed/Refractory Myeloma | Hans Lee, MD | ASCO 2023

ASCO 2023 Highlights To Look Forward To | Saad Usmani, MD | ASCO 2023